<DOC>
	<DOCNO>NCT00780208</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety Daytrana® treatment attention deficit hyperactivity disorder ( ADHD ) adult abuse stimulant past . Daytrana® stimulant medication approve Food Drug Administration treatment ADHD child age 6 year old .</brief_summary>
	<brief_title>Evaluating Methylphenidate Patch Treat Former Stimulant Users With ADHD</brief_title>
	<detailed_description>Methylphenidate amphetamine consider first line treatment ADHD child ( Biederman et al , 1997 ) . Although treat child adolescent stimulant appear increase risk substance use disorder ( Wilens et al , 2003 ) , little known abuse prescription stimulant adult ADHD . A review literature abuse potential methylphenidate animal human find methylphenidate produce reinforcing , discriminative-stimulus , subjective effect similar amphetamine cocaine ( Kollins et al , 2001 ) . Although abuse rate methylphenidate stimulant medication use treatment ADHD empirically establish , significant concern exist regulatory mandate enforce control distribution , physician may reluctant use stimulant patient drug abuse history . The introduction methylphenidate patch important advancement , patch formulation increase compliance minimize abuse potential , make attractive treatment option large population individual history previous drug misuse . The primary aim study assess efficacy methylphenidate patch adult individual ADHD abuse stimulant past . It hypothesize methylphenidate patch efficacious reduce ADHD symptom population .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>1 . Healthy men woman , 18 65 year age 2 . Meet DSMIV criterion past stimulant ( cocaine , methamphetamine , prescription stimulant ) abuse dependence , past abuse/dependence define minimum three month since meeting DSMIV criterion , exhibit pattern stimulant misuse . For purpose study , stimulant misuse define use someone else 's stimulant ADHD medication minimum four time onemonth period , misuse must occur least three month . 3 . Meet DSMIV criterion current ADHD , determine clinical interview confirm semistructured interview Conners ' Adult ADHD Diagnostic Interview DSMIV ( CAARD ; Conners et al , 1999 ) 4 . ADHD symptom severity indicate score 12 great WenderReimherr Adult Attention Deficit Disorder Scale 5 . All subject agree sign write , IRBapproved inform consent 6 . Subjects must live within 60mile radius Charleston , SC , facilitate study visit compliance 1 . Individuals meet DSMIV dependence substance exception nicotine caffeine 2 . Individuals meet DSMIV criterion lifetime history schizophrenia another nonaffective psychotic disorder bipolar disorder , since patient likely take psychotropic medication often require intensive psychiatric care 3 . Individuals meet DSMIV criterion current major depressive disorder eat disorder , since individual likely require treatment psychotropic medication . 4 . Individuals present significant suicidal risk 5 . Individuals significant cognitive impairment measure score less 26 MiniMental Status Exam , may unable understand inform consent , comply study protocol , accurately complete assessment 6 . Individuals currently receive stimulant , benzodiazepine , antidepressant antipsychotic medication . 7 . Individuals currently receive psychotherapy focus reduce ADHD symptom , could confound effect methylphenidate treatment 8 . Pregnant nursing woman , woman refuse use adequate birth control , methylphenidate approve use pregnancy 9 . Individuals without stable housing , contact individual would difficult 10 . Individuals major medical illness ( e.g. , HIV , renal failure , unstable angina , chronic obstructive pulmonary disease , infectious hepatitis ) 11 . Patients uncontrolled hypertension ( define blood pressure great 140/90 measure 3 occasion ) , methylphenidate treatment associate increase blood pressure 12 . Individuals significant family history cardiac abnormality , individual may susceptible cardiac adverse event 13 . Individuals obese ( great 30 % ideal weight BMI great 30 ) may interfere absorption methylphenidate 14 . Individuals , investigator ' opinion , would able comply study procedure , individual unable reliably present intake appointment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Attention Deficit Hyperactivity ADHD</keyword>
</DOC>